While the new drug reduced hematoma expansion compared with usual care, it was also associated with an increase in thrombotic events in the ANNEXa-I study.
The TENSION trial, which was stopped early for efficacy, selected patients using widely available non-contrast CT or CT angiography and should lead to more patients being considered for treatment.